Xarelto® (rivaroxaban) – New indication
October 11, 2018 - The FDA announced the approval of Xarelto (rivaroxaban), in combination with aspirin, to reduce the risk of major cardiovascular events (cardiovascular [CV] death, myocardial infarction [MI] and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Top